Search

Your search keyword '"Huber-Wechselberger, Ariana"' showing total 6 results
Start Over Author "Huber-Wechselberger, Ariana"
6 results on '"Huber-Wechselberger, Ariana"'

4. Intraplatform Reproducibility and Technical Precision of Gene Expression Profiling in 4 Laboratories Investigating 160 Leukemia Samples: The DACH Study

Author

Kohlmann, Alexander, primary, Haschke-Becher, Elisabeth, primary, Wimmer, Barbara, primary, Huber-Wechselberger, Ariana, primary, Meyer-Monard, Sandrine, primary, Huxol, Heike, primary, Siegler, Uwe, primary, Rossier, Michel, primary, Matthes, Thomas, primary, Rebsamen, Michela, primary, Chiappe, Alberto, primary, Diemand, Adeline, primary, Rauhut, Sonja, primary, Johnson, Andrea, primary, Liu, Wei-min, primary, Williams, P Mickey, primary, Wieczorek, Lothar, primary, and Haferlach, Torsten, primary

Published
2008
Full Text
View/download PDF

5. Intraplatform Reproducibility and Technical Precision of Gene Expression Profiling in Four Laboratories Investigating 112 Leukemia Samples: The DACH Study.

Author

Kohlmann, Alexander, primary, Haschke-Becher, Elisabeth, primary, Wimmer, Barbara, primary, Huber-Wechselberger, Ariana, primary, Meyer-Monard, Sandrine, primary, Huxol, Heike, primary, Siegler, Uwe, primary, Rossier, Michel, primary, Matthes, Thomas, primary, Rebsamen, Michela, primary, Diemand, Adeline, primary, Chiappe, Alberto, primary, Rauhut, Sonja, primary, Liu, Wei-min, primary, Johnson, Andrea, primary, Wieczorek, Lothar, primary, and Haferlach, Torsten, primary

Published
2007
Full Text
View/download PDF

6. Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer.

Author

Parmar, Sumit, Stingl, Julia Carolin, Huber-Wechselberger, Ariana, Kainz, Alexander, Renner, Wilfried, Langsenlehner, Uwe, Krippl, Peter, Brockmöller, Jürgen, and Haschke-Becher, Elisabeth

Subjects
BREAST cancer treatment, GENETIC polymorphisms, CANCER patients, REGRESSION analysis, METASTASIS
Abstract

Introduction: Epirubicin is a common adjuvant treatment for breast cancer. It is mainly eliminated after glucuronidation through uridine diphosphate-glucuronosyltransferase 2B7 (UGT2B7). The present study aimed to describe the impact of the UGT2B7His268Tyr polymorphism on invasive disease-free survival in breast cancer patients after epirubicin treatment. Methods: This is a pharmacogenetic study based on samples collected from 745 breast cancer patients of the Austrian Tumor of breast tissue: Incidence, Genetics, and Environmental Risk factors (TIGER) cohort who did not present metastases at baseline. This cohort included 205 women with epirubicin-based combination chemotherapy, 113 patients having received chemotherapy without epirubicin and 427 patients having received no chemotherapy at all. Of the epirubicin-treated subgroup, 120 were subsequently treated with tamoxifen. For all women UGT2B7His268Tyr was genotyped. Invasive disease-free survival was assessed using Kaplan-Meier and Cox's proportional hazard regression analysis. Results: Among the 205 epirubicin-treated patients, carriers of two UGT2B7268Tyr alleles had a mean invasive disease-free survival of 8.6 (95% confidence interval (CI) 7.9 to 9.3) years as compared to 7.5 (95% CI 6.9 to 8.0) years in carriers of at least one UGT2B7268His allele (adjusted hazard ratio (HR) = 2.64 (95% CI 1.22 to 5.71); P = 0.014). In addition, the impact of the UGT2B7His268Tyr polymorphism became even more pronounced in patients subsequently treated with tamoxifen (adjusted HR = 5.22 (95% CI 1.67 to 26.04); P = 0.015) whereas no such difference in invasive disease-free survival was observed in patients not receiving epirubicin. Conclusions: Breast cancer patients carrying the UGT2B7268Tyr/Tyr genotype may benefit most from adjuvant epirubicin-based chemotherapy. These results warrant confirmation in further studies. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results